These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38129782)

  • 1. Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma.
    Xu H; Li W; Zhang H; Wang H; Hu L; Gu Y; Wang D
    BMC Cancer; 2023 Dec; 23(1):1259. PubMed ID: 38129782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopic surgery versus intensity-modulated radiotherapy in locally advanced recurrent nasopharyngeal carcinoma: a multicenter, case-matched comparison.
    Liu Y; Huang N; Gao J; He B; Huang H; Wan L; Cai Q; Zhu Z; Zhou S; Wang J; Wang X; Qiu Q; Han F
    J Otolaryngol Head Neck Surg; 2023 Nov; 52(1):72. PubMed ID: 37932841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopic Nasopharyngectomy Combined With Internal Carotid Artery Pretreatment for Recurrent Nasopharyngeal Carcinoma.
    Wang ZQ; Xie YL; Liu YP; Zou X; Chen JH; Hua YJ; Gu YK; Ouyang YF; Yu ZK; Sun R; Huang PY; Chen MY
    Otolaryngol Head Neck Surg; 2022 Mar; 166(3):490-497. PubMed ID: 34182810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma – A case-matched comparison.
    You R; Zou X; Hua YJ; Han F; Li L; Zhao C; Hong MH; Chen MY
    Radiother Oncol; 2015 Jun; 115(3):399-406. PubMed ID: 25987536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Liu YP; Wen YH; Tang J; Wei Y; You R; Zhu XL; Li J; Chen L; Ling L; Zhang N; Zou X; Hua YJ; Chen YM; Chen L; Lu LX; Chen MY; Wen WP
    Lancet Oncol; 2021 Mar; 22(3):381-390. PubMed ID: 33600761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma.
    Liu YP; Lv X; Zou X; Hua YJ; You R; Yang Q; Xia L; Guo SY; Hu W; Zhang MX; Chen SY; Lin M; Xie YL; Liu LZ; Sun R; Huang PY; Fan W; Guo X; Hong MH; Chen MY
    Cancer Commun (Lond); 2019 Nov; 39(1):75. PubMed ID: 31730020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel endoscopic nasopharyngectomy by low-temperature plasma radiofrequency ablation in localized recurrent nasopharyngeal carcinoma.
    Zou X; Feng ZK; Hua YJ; Liu YP; Xie YL; Ouyang YF; Liu YL; Wang ZQ; You R; Ding X; Yang Q; Yu ZK; Huang PY; Wang SL; Chen MY
    Head Neck; 2024 Feb; 46(2):291-299. PubMed ID: 37974339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma.
    Zhang B; Li Y; Weng J; Huang B; Ban M; Lan G; Lu Y; Luo J; Qu S; Si Y
    Technol Cancer Res Treat; 2021; 20():15330338211011975. PubMed ID: 33896244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage Endoscopic Skull Base Surgery: Another Treatment Option After Immunotherapy for Recurrent Nasopharyngeal Carcinoma.
    Peng Z; Wang Y; Fang Y; Wang Y; Yuan X; Shuai M; Xie S; Fan R; Zhang H; Xie Z; Jiang W
    Front Immunol; 2022; 13():899932. PubMed ID: 35686123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.
    Sun H; Bu F; Li L; Zhang X; Xin X; Yan J; Huang T
    Ann Pharmacother; 2024 Apr; 58(4):349-359. PubMed ID: 37488978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for patients with recurrent nasopharyngeal carcinoma involved internal carotid artery who are intolerant to embolization.
    Wu WB; Zhang XB; Feng ZK; Li HF; Liu YP; Liang JL; Xie YL; Hua YJ; Sun R; Wang SL; Chen JH; Chen MY
    Rhinology; 2024 Jun; 62(3):342-352. PubMed ID: 38078376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of nasopharyngectomy in the management of nasopharyngeal carcinoma.
    Wang WH; Yeh CF; Lan MY
    Curr Opin Otolaryngol Head Neck Surg; 2022 Feb; 30(1):3-12. PubMed ID: 34958319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
    Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi YR; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Liu Z; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Feng H; Yao S; Keegan P; Xu RH
    Nat Med; 2021 Sep; 27(9):1536-1543. PubMed ID: 34341578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-year outcomes of salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma.
    Thamboo A; Patel VS; Hwang PH
    J Otolaryngol Head Neck Surg; 2021 Feb; 50(1):12. PubMed ID: 33597031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy.
    Jiang Y; Chen C; Liu G; Fang T; Lu N; Bei W; Dong S; Li W; Xia W; Liang H; Xiang Y
    Sci Rep; 2024 Jan; 14(1):1768. PubMed ID: 38242940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
    Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
    JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness of endoscopic nasopharyngectomy in locally recurrent rT1-rT3 nasopharyngeal carcinoma: a study based on Markov model].
    Chen MY; Wen WP; Li J; Liu YP; Chen MY; Tang J; Wen YH
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Nov; 57(11):1304-1310. PubMed ID: 36404655
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative effectiveness and cost-effectiveness of endoscopic nasopharyngectomy versus intensity-modulated radiotherapy in the treatment of recurrent nasopharyngeal carcinoma: A microsimulation analysis.
    Rui M; Wang Y
    Head Neck; 2024 Sep; ():. PubMed ID: 39311280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
    Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
    JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.